IL157415A0 - Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides - Google Patents

Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides

Info

Publication number
IL157415A0
IL157415A0 IL15741502A IL15741502A IL157415A0 IL 157415 A0 IL157415 A0 IL 157415A0 IL 15741502 A IL15741502 A IL 15741502A IL 15741502 A IL15741502 A IL 15741502A IL 157415 A0 IL157415 A0 IL 157415A0
Authority
IL
Israel
Prior art keywords
protein
dna sequence
codon
lys
arg
Prior art date
Application number
IL15741502A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL157415A0 publication Critical patent/IL157415A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
IL15741502A 2001-02-20 2002-02-08 Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides IL157415A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108100A DE10108100A1 (de) 2001-02-20 2001-02-20 Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
PCT/EP2002/001306 WO2002066628A2 (en) 2001-02-20 2002-02-08 Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides

Publications (1)

Publication Number Publication Date
IL157415A0 true IL157415A0 (en) 2004-03-28

Family

ID=7674831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15741502A IL157415A0 (en) 2001-02-20 2002-02-08 Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides

Country Status (21)

Country Link
EP (1) EP1364030B1 (es)
JP (1) JP4243103B2 (es)
KR (1) KR100858008B1 (es)
CN (1) CN100575493C (es)
AT (1) ATE320498T1 (es)
AU (1) AU2002247696B2 (es)
BR (1) BR0207385A (es)
CA (1) CA2438935C (es)
CY (1) CY1105696T1 (es)
DE (2) DE10108100A1 (es)
DK (1) DK1364030T3 (es)
ES (1) ES2258619T3 (es)
HK (1) HK1065818A1 (es)
IL (1) IL157415A0 (es)
MX (1) MXPA03007115A (es)
NO (1) NO331375B1 (es)
NZ (1) NZ527641A (es)
PE (1) PE20020875A1 (es)
PT (1) PT1364030E (es)
WO (1) WO2002066628A2 (es)
ZA (1) ZA200305867B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613661B1 (en) * 2003-04-04 2011-06-29 Université de Lausanne Peptabody for cancer treatment
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
KR101972301B1 (ko) 2009-11-13 2019-04-25 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
CA2809321C (en) 2010-08-30 2018-08-14 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108866205A (zh) * 2018-07-25 2018-11-23 中国食品药品检定研究院 基于分子生物学方法鉴别菲牛蛭的特异性引物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347781B1 (de) * 1988-06-23 1994-02-16 Hoechst Aktiengesellschaft Mini-Proinsulin, seine Herstellung und Verwendung
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista

Also Published As

Publication number Publication date
AU2002247696B2 (en) 2006-10-12
PE20020875A1 (es) 2002-10-31
KR20030074832A (ko) 2003-09-19
MXPA03007115A (es) 2003-11-18
DK1364030T3 (da) 2006-07-17
WO2002066628A3 (en) 2002-11-14
ZA200305867B (en) 2004-06-29
CN100575493C (zh) 2009-12-30
WO2002066628A2 (en) 2002-08-29
KR100858008B1 (ko) 2008-09-11
NO20033671D0 (no) 2003-08-19
EP1364030B1 (en) 2006-03-15
DE60209883T2 (de) 2006-09-07
PT1364030E (pt) 2006-05-31
NO20033671L (no) 2003-10-17
CA2438935A1 (en) 2002-08-29
DE10108100A1 (de) 2002-08-29
NZ527641A (en) 2005-03-24
DE60209883D1 (de) 2006-05-11
JP2004518442A (ja) 2004-06-24
CN1527882A (zh) 2004-09-08
ATE320498T1 (de) 2006-04-15
BR0207385A (pt) 2004-02-10
CA2438935C (en) 2012-01-24
CY1105696T1 (el) 2010-12-22
HK1065818A1 (en) 2005-03-04
EP1364030A2 (en) 2003-11-26
NO331375B1 (no) 2011-12-12
ES2258619T3 (es) 2006-09-01
JP4243103B2 (ja) 2009-03-25

Similar Documents

Publication Publication Date Title
CY1105696T1 (el) Υπερεκκρινομενα πεπτιδια, διεργασιες για την παραγωγη τους και παραλληλη βελτιωση του εκκρινομενου ειδους ενος ή περισσοτερων αλλων πεπτιδιων
EP0651761B1 (en) Method for modification of recombinant polypeptides
CY1106274T1 (el) Χρηση πρωτεϊνων συντηξης των οποιων το ν-τελικο τμημα ειναι ενα παραγωγο ιρουδινης για την παραγωγη ανασυνδυασμενων πρωτεϊνων μεσω εκκρισης απο ζυμομυκητα
NO965411L (no) N-terminalt forlengede proteiner uttrykt i gjær
Acher et al. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport
ATE421977T1 (de) Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
JP2010265287A (ja) ペプチドアミド化方法
DE69739013D1 (de) Verfahren zur Herstellung sekretorischer KEX2-Derivate
CA2324513A1 (en) Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production
BG101226A (en) Method for the preparation of a modified inhibitor palidipine of collagen-induced thrombocyte accumulation
US5656456A (en) Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
JP5909812B2 (ja) 生物的に生成される環状アフィニティータグ
ES2316588T3 (es) Metodo para hacer polipeptidos acilados.
GR3016981T3 (en) Signal peptide and DNA sequences coding thereof.
WO2004011599A2 (en) Polypeptide cleavage process

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees